Bavarian Nordic Aktie
WKN: 917165 / ISIN: DK0015998017
|
10.11.2016 17:30:24
|
Bavarian Nordic to Present at Jefferies 2016 London Healthcare Conference
COPENHAGEN, Denmark - November 10, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Ole Larsen, Executive Vice President & CFO will provide a corporate presentation at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016 at 12:40 p.m. GMT.
The presentation slides will subsequently be available on the Company's website www.bavarian-nordic.com under "Investors > Events & Presentations".
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43
U.S.: Seth Lewis, Vice President, Investor Relations & Communications. Phone: +1 978 341 5271
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bavarian Nordic A/Smehr Nachrichten
|
04.03.25 |
Ausblick: Bavarian Nordic vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
|
28.02.25 |
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older (GlobeNewswire) | |
|
18.02.25 |
Erste Schätzungen: Bavarian Nordic zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) | |
|
14.02.25 |
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older (GlobeNewswire) | |
|
03.02.25 |
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025 (GlobeNewswire) | |
|
31.01.25 |
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older (GlobeNewswire) | |
|
16.12.24 |
ROUNDUP/Wegen Mpox: Schule in NRW vorsorglich geschlossen (dpa-AFX) | |
|
11.12.24 |
Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program (GlobeNewswire) |
Analysen zu Bavarian Nordic A/Smehr Analysen
Aktien in diesem Artikel
| Bavarian Nordic A/S | 20,95 | -0,24% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.